Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2016

View Archived Issues

CombiMatrix launches preimplantation genetic diagnosic test CombiPGD

Pfizer and Allergan announce termination of proposed merger agreement

Kamada initiates phase II study with intravenous alpha1-antitrypsin

Regeneron and MedImmune enter agreement to develop ADCs for the treatment of cancer

Bayer Schering Pharma patents factor XIa and KLKB1 inhibitors

AbbVie discloses HAT inhibitors

Ironwood Pharmaceuticals describes sGC activators

FORMA Therapeutics develops mutant-isocitrate dehydrogenase inhibitors

Epizyme presents lysine-specific demethylase inhibitors

Janssen and Tesaro announces global prostate cancer collaboration

PSMA1 shows potential as a prognostic biomarker for colon cancer

FDA grants orphan drug designation to 9-ING-41 for the treatment of glioblastoma

BIND Therapeutics reports topline data from phase II iNSITE 1 and 2 trials

Bristol-Myers Squibb's Opdivo approved in new indication in E.U.

TCF3 may be a useful biomarker to discriminate between seminomatous and non-seminomatous GCTs

MorphoSys and Galapagos begin clinical trials of MOR-106

Peptidream announces research agreement with BIND Therapeutics

Alpha Cancer's AFP assets for oncology and autoimmune diseases

SanBio cleared in Japan to conduct phase II trial of stem cell therapy

Pasireotide lowers plasma ACTH levels in patients with Nelson's syndrome

Allergan and Heptares announce commercialization agreement for novel neurologic disease therapies

Novartis' Revolade now approved for pediatric patients in E.U.

Afatinib approved in Europe for squamous cell carcinoma of the lung

Dako launches test for nivolumab survival benefit in non-squamous NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.